Design, Synthesis, and Biological Evaluation of Icaritin Derivatives as Novel Putative DEPTOR Inhibitors for Multiple Myeloma Treatment

Authors:

Abstract
Icaritin is an active ingredient in Epimedium, which has a variety of pharmacological activities. However, the low activity of Icaritin and the unclear target greatly limit its application. Therefore, based on the structure of Icaritin, we adopted the strategy of replacing toxic groups and introducing active groups to design and synthesize a series of new analogues. The top compound C3 exhibited better antimultiple myeloma activity with an IC50 of 1.09 μM for RPMI 8226 cells, induced RPMI 8226 apoptosis, and blocked the cell cycle in the S phase. Importantly, transcriptome analysis, cellular thermal shift assay, and microscale thermophoresis assay confirmed that DEPTOR was the target of C3. Moreover, we explored its binding mode with C3. Especially, C3 displayed satisfactory inhibition of tumor growth in RPMI 8226 xenografts without obvious side effects. In summary, C3 was discovered as a novel putative inhibitor of DEPTOR for the treatment of multiple myeloma.
Funding Information
  • Ministry of Education of the People's Republic of China (CPU2018GF04)
  • National Natural Science Foundation of China (31900687, 82073701)
  • State Key Laboratory of Natural Medicines, China Pharmaceutical University (SKLNMZZ202013)
  • Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University (2020KFKT-5, DDORC201801)

This publication has 37 references indexed in Scilit: